Report Detail
Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Insights, Forecast to 2025
- RnM2394064 |
- 03 April, 2019 |
- Global |
- 117 Pages |
- QYResearch |
- Pharma & Healthcare
The global B-Cell Maturation Antigen(BCMA) Targeted Therapies market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the B-Cell Maturation Antigen(BCMA) Targeted Therapies market based on company, product type, end user and key regions.
This report studies the global market size of B-Cell Maturation Antigen(BCMA) Targeted Therapies in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of B-Cell Maturation Antigen(BCMA) Targeted Therapies in these regions.
This research report categorizes the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market by top players/brands, region, type and end user. This report also studies the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics
Market size by Product
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells
Market size by End User
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of B-Cell Maturation Antigen(BCMA) Targeted Therapies market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global B-Cell Maturation Antigen(BCMA) Targeted Therapies companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of B-Cell Maturation Antigen(BCMA) Targeted Therapies submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of B-Cell Maturation Antigen(BCMA) Targeted Therapies are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of B-Cell Maturation Antigen(BCMA) Targeted Therapies market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size Growth Rate by Product
- 1.4.2 Bispecific Antibodies
- 1.4.3 Antibody Drug Conjugates
- 1.4.4 Chimeric Antigen Receptor T-Cells
- 1.5 Market by End User
- 1.5.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size Growth Rate by End User
- 1.5.2 Liver Cancer
- 1.5.3 Respiratory Cancer
- 1.5.4 Brain Cancer
- 1.5.5 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size
- 2.1.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue 2014-2025
- 2.1.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales 2014-2025
- 2.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Growth Rate by Regions
- 2.2.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales by Regions
- 2.2.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales by Manufacturers
- 3.1.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales by Manufacturers
- 3.1.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Manufacturers
- 3.1.3 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Concentration Ratio (CR5 and HHI)
- 3.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Manufacturers
- 3.2.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Manufacturers (2014-2019)
- 3.2.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Manufacturers (2014-2019)
- 3.3 B-Cell Maturation Antigen(BCMA) Targeted Therapies Price by Manufacturers
- 3.4 B-Cell Maturation Antigen(BCMA) Targeted Therapies Manufacturing Base Distribution, Product Types
- 3.4.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Type
- 3.4.3 Date of International Manufacturers Enter into B-Cell Maturation Antigen(BCMA) Targeted Therapies Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales by Product
- 4.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Product
- 4.3 B-Cell Maturation Antigen(BCMA) Targeted Therapies Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Breakdown Data by End User
6 North America
- 6.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies by Countries
- 6.1.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales by Countries
- 6.1.2 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies by Product
- 6.3 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies by End User
7 Europe
- 7.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies by Countries
- 7.1.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales by Countries
- 7.1.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies by Product
- 7.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies by End User
8 Asia Pacific
- 8.1 Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies by Countries
- 8.1.1 Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales by Countries
- 8.1.2 Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies by Product
- 8.3 Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies by End User
9 Central & South America
- 9.1 Central & South America B-Cell Maturation Antigen(BCMA) Targeted Therapies by Countries
- 9.1.1 Central & South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales by Countries
- 9.1.2 Central & South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America B-Cell Maturation Antigen(BCMA) Targeted Therapies by Product
- 9.3 Central & South America B-Cell Maturation Antigen(BCMA) Targeted Therapies by End User
10 Middle East and Africa
- 10.1 Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies by Countries
- 10.1.1 Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales by Countries
- 10.1.2 Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies by Product
- 10.3 Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies by End User
11 Company Profiles
- 11.1 Transposagen Biopharmaceuticals
- 11.1.1 Transposagen Biopharmaceuticals Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Products Offered
- 11.1.5 Transposagen Biopharmaceuticals Recent Development
- 11.2 Sutro Biopharma
- 11.2.1 Sutro Biopharma Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Products Offered
- 11.2.5 Sutro Biopharma Recent Development
- 11.3 Malin Corporation
- 11.3.1 Malin Corporation Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Products Offered
- 11.3.5 Malin Corporation Recent Development
- 11.4 Eureka Therapeutics
- 11.4.1 Eureka Therapeutics Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Products Offered
- 11.4.5 Eureka Therapeutics Recent Development
- 11.5 firstVentury Equity
- 11.5.1 firstVentury Equity Company Details
- 11.5.2 Company Business Overview
- 11.5.3 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Products Offered
- 11.5.5 firstVentury Equity Recent Development
- 11.6 Five Prime Therapeutics
- 11.6.1 Five Prime Therapeutics Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Products Offered
- 11.6.5 Five Prime Therapeutics Recent Development
- 11.7 Credit Suisse Securities
- 11.7.1 Credit Suisse Securities Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Products Offered
- 11.7.5 Credit Suisse Securities Recent Development
- 11.8 Dana-Farber Cancer Institute
- 11.8.1 Dana-Farber Cancer Institute Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Products Offered
- 11.8.5 Dana-Farber Cancer Institute Recent Development
- 11.9 Deerfield Partners
- 11.9.1 Deerfield Partners Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Products Offered
- 11.9.5 Deerfield Partners Recent Development
- 11.10 Onyx Pharmaceuticals
- 11.10.1 Onyx Pharmaceuticals Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Products Offered
- 11.10.5 Onyx Pharmaceuticals Recent Development
- 11.11 Juno Therapeutics
12 Future Forecast
- 12.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Forecast by Regions
- 12.1.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Forecast by Regions 2019-2025
- 12.1.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Forecast by Regions 2019-2025
- 12.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Forecast by Product
- 12.2.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Forecast by Product 2019-2025
- 12.2.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Forecast by Product 2019-2025
- 12.3 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Forecast by End User
- 12.4 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecast
- 12.5 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecast
- 12.6 Asia Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecast
- 12.7 Central & South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecast
- 12.8 Middle East and Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on B-Cell Maturation Antigen(BCMA) Targeted Therapies . Industry analysis & Market Report on B-Cell Maturation Antigen(BCMA) Targeted Therapies is a syndicated market report, published as Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
